Sertraline

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Both combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported internalizing psychopathology, while CBT alone was not.

Effect: improvement; COMB: b=-5.7, t=3.4; SRT: b=-6.8, t=4.0

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8

Combination treatment and sertraline monotherapy were superior to placebo at week 12 on parent-reported youth depressive symptoms, while CBT was not, with both COMB and SRT also superior to CBT.

Effect: improvement; COMB: b= -3.9, t= -3.7; SRT: b= -3.0, t= -2.8